Free Trial

Xyratex (XRTX) Competitors

Notice: This company has been marked as potentially delisted and may not be actively trading.

XRTX vs. YMTX, NRBO, VINC, INDP, LUMO, SNSE, IBIO, PPBT, SYBX, and VBIV

Should you be buying Xyratex stock or one of its competitors? The main competitors of Xyratex include Yumanity Therapeutics (YMTX), NeuroBo Pharmaceuticals (NRBO), Vincerx Pharma (VINC), Indaptus Therapeutics (INDP), Lumos Pharma (LUMO), Sensei Biotherapeutics (SNSE), iBio (IBIO), Purple Biotech (PPBT), Synlogic (SYBX), and VBI Vaccines (VBIV). These companies are all part of the "pharmaceutical preparations" industry.

Xyratex vs.

Xyratex (NASDAQ:XRTX) and Yumanity Therapeutics (NASDAQ:YMTX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, community ranking, risk, media sentiment and institutional ownership.

In the previous week, Xyratex had 1 more articles in the media than Yumanity Therapeutics. MarketBeat recorded 1 mentions for Xyratex and 0 mentions for Yumanity Therapeutics. Xyratex's average media sentiment score of 0.00 equaled Yumanity Therapeutics'average media sentiment score.

Company Overall Sentiment
Xyratex Neutral
Yumanity Therapeutics Neutral

Xyratex has higher earnings, but lower revenue than Yumanity Therapeutics. Xyratex is trading at a lower price-to-earnings ratio than Yumanity Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XyratexN/AN/A-$2.16M-$1.34-1.93
Yumanity Therapeutics$4.84M1.03-$39.50M-$3.00-0.15

Xyratex received 142 more outperform votes than Yumanity Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Yumanity Therapeutics an outperform vote while only 63.41% of users gave Xyratex an outperform vote.

CompanyUnderperformOutperform
XyratexOutperform Votes
156
63.41%
Underperform Votes
90
36.59%
Yumanity TherapeuticsOutperform Votes
14
70.00%
Underperform Votes
6
30.00%

0.2% of Xyratex shares are owned by institutional investors. Comparatively, 25.1% of Yumanity Therapeutics shares are owned by institutional investors. 6.9% of Xyratex shares are owned by company insiders. Comparatively, 12.5% of Yumanity Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xyratex has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, Yumanity Therapeutics has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.

Xyratex currently has a consensus target price of $14.00, suggesting a potential upside of 442.64%. Given Xyratex's higher probable upside, analysts plainly believe Xyratex is more favorable than Yumanity Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xyratex
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Yumanity Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Xyratex has a net margin of 0.00% compared to Yumanity Therapeutics' net margin of -660.61%. Xyratex's return on equity of -135.54% beat Yumanity Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XyratexN/A -135.54% -107.64%
Yumanity Therapeutics -660.61%-263.34%-107.08%

Summary

Xyratex beats Yumanity Therapeutics on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XRTX vs. The Competition

MetricXyratexPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.16M$7.00B$5.15B$8.05B
Dividend YieldN/A2.76%2.78%3.96%
P/E Ratio-1.9322.52150.3018.46
Price / SalesN/A240.192,487.9671.55
Price / CashN/A33.1636.2631.15
Price / Book2.065.755.384.56
Net Income-$2.16M$148.70M$106.56M$214.11M

Xyratex Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
YMTX
Yumanity Therapeutics
0 of 5 stars
$0.46
-2.1%
N/A-85.0%$20.52M$4.84M-0.1540Gap Up
NRBO
NeuroBo Pharmaceuticals
2.4458 of 5 stars
$4.13
+3.8%
$10.00
+142.1%
-9.2%$20.28MN/A0.008
VINC
Vincerx Pharma
3.0333 of 5 stars
$0.68
-2.8%
$5.00
+631.2%
-57.8%$20.20MN/A-0.3842Positive News
Gap Up
INDP
Indaptus Therapeutics
3.1443 of 5 stars
$2.34
-0.8%
$12.00
+412.8%
+28.6%$19.98MN/A-1.317Positive News
LUMO
Lumos Pharma
1.5923 of 5 stars
$2.45
-2.0%
$18.00
+634.4%
-33.4%$19.90M$2.05M-0.5333
SNSE
Sensei Biotherapeutics
4.637 of 5 stars
$0.79
-45.5%
$4.50
+469.6%
-42.8%$19.81MN/A-0.6528Analyst Forecast
News Coverage
Gap Down
High Trading Volume
IBIO
iBio
0 of 5 stars
$2.19
-0.9%
N/AN/A$18.88M$2.38M0.0026Positive News
PPBT
Purple Biotech
1.7967 of 5 stars
$0.75
-7.5%
$9.00
+1,108.1%
-59.1%$18.80MN/A-0.9220Analyst Forecast
Analyst Revision
News Coverage
Gap Up
High Trading Volume
SYBX
Synlogic
2.7135 of 5 stars
$1.60
+1.3%
$65.00
+3,962.5%
-80.4%$18.74M$3.37M-0.166Gap Up
VBIV
VBI Vaccines
1.3567 of 5 stars
$0.65
+3.2%
N/A-76.7%$18.61M$8.68M0.00131

Related Companies and Tools

This page (NASDAQ:XRTX) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners